Select Page
Grigoris Gerotziafas
Adjunct Professor, Hematology
G.Gerotziafas@external.euc.ac.cy
22559410
The School of Medicine
Medicine
Academic Qualifications
Qualification Year Awarding Institution Department Thesis title (Optional Entry)
University degree of Medical Doctor 1991 Aristotle University of Thessaloniki, Greece. Faculty of Medicine
Diplôme d’Études Approfondies (equivalent to Master 2) in Pathogenesis of Thrombosis 1994 University Pierre et Marie Curie,France Faculty of Medicine Broussais Hotel-Dieu
PhD degree on Cardiovascular Pharmacology 1999 University Pierre et Marie Curie,Paris VI, France Faculty of Medicine "Génération du FVIIa pendant la coagulation du plasma humain. Etude du mécanisme d’inhibition de la génération et de l’activité du FVIIa induite par le pentasaccharide synthétique, l’héparine de bas poids moléculaire et l’héparine non fractionnée. Comparaison avec l’hirudine recombinante"
Postdoctoral- Laboratory of Biochemistry 1999-2002 University of Thessaloniki, Greece. Faculty of Chemisty
Qualification as specialist in Hematology 2002 Greek and European Union Health Authorities
Habilitation à Diriger la Recherche 2016 University Pierre et Marie Curie (Paris VI) Faculty of Medicine
Employment History
Period of employment Employer Location Position
From To
01/06/2002 31/12/2002 Department of Emergency, University Hospital Hotel-Dieu Paris, France Assistance Publique Hopitaux de Paris
26/9/2003 30/9/2005 Department of Haemostasis, Hospital Robert Debrι Paris, France
1/11/2005 31/08/2008 Department of Haemostasis, University Hospital Tenon, University Pierre et Marie Curie Paris, France
01/09/2008 Ongoing University Hτpital Tenon, Assistance Publique Hτpitaux de Paris, University Pierre et Marie Curie, Paris VI. Paris, France
Publications
Year Title Other authors Journal and Publisher / Conference Vol. Pages
2018 Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation Chaussade E, Hanon O, Boully C, Labourιe F, Caillard L, Gerotziafas G, Vidal JS, Elalamy I. J Nutr Health Aging 22 165-173
2018 Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation Chaussade E, Hanon O, Boully C, Labourιe F, Caillard L, Gerotziafas G, Vidal JS, Elalamy I. J Nutr Health Aging 22 165-173
2013 Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma. Papageorgiou C, Vandreden P, Marret E, Bonnet F, Robert F, Spyropoulos A, Galea V, Elalamy I, Hatmi M, Gerotziafas GT. Thromb Res 132 584-91.
2012 The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, Stankovic-Stojanovic K, Blanc-Brude O, Woodhams B, Maier-Redelsperger M, Girot R, Hatmi M, Elalamy I. Thromb Haemost 107 1044-52
2017 Gavaises M.Modelling of thrombin generation under flow in realistic left anterior descending geometries Papadopoulos KP, Gerotziafas GT Med Eng Phys 50 50-58
2017 Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study Gerotziafas GT, Van Dreden P, Mathieu d'Argent E, Lefkou E, Grusse M, Comtet M, Sangare R,Ketatni H, Larsen AK, Elalamy I Thromb J. 15 9
2016 Rapid detection of D-Dimers with mLabs® whole blood method for venous thromboembolism exclusion. Comparison with Vidas® D-Dimers assay Gerotziafas GT, Ray P, Gkalea V, Benzarti A, Khaterchi A, Cast C, Pernet J, Lefkou E, Elalamy I Int Angiol. 35 622-628
2007 Prophylaxis for venous thrombosis in medical and surgical patients. Womens’ vascular health Gerotziafas GT, Samama MM. Hodder Arnold. Editι par Greer I, Ginsberg J, Forbes CD. 171-185.
2017 Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer. Rousseau A, Van Dreden P,Khaterchi A, Larsen AK, Elalamy I, Gerotziafas GT. Int J Oncol. 51 1793-1800
2015 Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin, Rousseau A, Van Dreden P, Mbemba E, Elalamy I, Larsen A, Gerotziafas GT Thromb Res 136 1273-9
1998 Comparative effects of synthetic pentasaccharide, low molecular weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Blood Coagul Fibrinolysis 9 571-580.
Exhibitions
Research Projects
Title Funded by Project Role*
Modelisation of the interaction of cells from solid cancers or haematological malignancies with the vascular and haemostatic components of the microenvironment and related alterations in the activity of antithrombotic and anticancer agents. Principal Investigator and Academic Supervisor
Modelisation of the link between vascular mimicry properties of cancer cells and modulation of blood coagulation. Principal Investigator and Academic Supervisor
Pharmacological and functional characterization of heparins and glycosaminoglycan derivatives Principal Investigator and Academic Supervisor
Development of clinico-biological risk assessment models for the identification of patients with solid cancers or haematological malignancies at risk of cancer associated thrombosis. Translational research
Clinical trials on the prevention of cancer associated thrombosis Translational research
Development of diagnostic strategies for the biological monitoring of treatment treatment with direct orally active anticoagulants Translational research>
ROADMAP-IVF: Prospective risk assessment and biomarkers of hypercoagulability for the identification of women eligible for in vitro fertilization at risk of negative pregnancy outcome. International observational study in collaboration with Dr. E Mathieu and Pr. N. Buffet, Service de Gynecologie Hτpital Tenon, Paris, France et Pr. Tarlatzis, Department of Gynecology Papageorgiou Hospital Thessaloniki Greece. International, multicenter clinical studies
ATICKS study: AntiThrombotics' Impact on Clot formation Kinetics and Structure. Clinicobiological study. Evaluation of the effect of direct orally active anticoagulants and low molecular weight heparins on thrombin generation and clot formation kinetics and physical characteristics. International, multicenter clinical studies
PRONIA-CAT: Thromboprophylaxis of Metastatic cancer patients with the low molecular weight heparin tinzaparin. Long term prevention of venous thromboembolism with low dose tinzaparin in patients with breast or prostate cancer at high risk for cancer associated thrombosis. A prospective, randomized, international multicenter, placebo controlled, open-label, blinded-endpoint study. A Phase III investigator initiated study on 1400 patients. Patients' recruitment will start in the first trimester of 2018. International, multicenter clinical studies
COMPASS-CAT: Prospective multicenter international observational study for derivation of a new risk assessment model for cancer associated thrombosis in ambulatory patients on chemotherapy for breast, colorectal, lung, or ovarian Cancer. This project has been organized in collaboration with experts of Middle East, Greece, France, USA, has already given une publication (The Oncologist 2017) and is continued with the elaboration of strategies for implementation of the predictive tools and guidelines for prevention of cancer associated thrombosis in real life clinical practice. International, multicenter clinical studies
HeparinFuture: Pharmacological analysis and identification of the anticoagulant properties of heparin dérivatives and biosimilars. Project in collaboration with the Department of Pathology and Pharmacology, Stritch School of Medicine, Loyola University, Chicago USA (Prof J Fareed et Prof J Walega). International, multicenter clinical studies
Academic Consulting Services/Councils/Boards/Editorial Committees
Organization Title of Position or Service Key Activities
Faculty de Medicine, University Pierre et Marie Curie, Paris VI. Theoretical courses and practical seminars on Haemostasis and Thrombosis to the students of the Teaching
Faculty de Medicine, University Pierre et Marie Curie, Paris VI. Theoretical courses and practical seminars on Haemostasis and Thrombosis to the students of the Teaching
International Union of Angiology Member of the administration board of VAS – Vascular Independent Research and Education European Foundation, endorsed Appointments as an expert in the field of thrombosis and haemostasis
Member of the Editorial Board of the International Conference on Thrombosis and Hemostasis Issues in Cancer Magazine
Member of the administration board of VAS – Vascular Independent Research and Education European Foundation, endorsed by the International Union of Angiology
Chairman of the national Hellenic committee for the therapeutic protocols for the prevention and treatment of venous thromboembolic disease, endorsed by the Greek Ministry of Health.
Awards/International Recognition
Date Title
2000 International Society of Thrombosis
STAGO Award for innovative research in Thrombosis and Haemostasis
2008 Haemostasis young investigator award
2017,2018  ISTH award for best poster presentation
Other Achievements